EGFR and non-small cell lung carcinoma: Two previous phase 2 neoadjuvant chemoimmunotherapy trials reported excellent pathological response in EGFR-mutated NSCLC, which was underpowered by the small sample (Provencio et al., 2020; Shu et al., 2020).